Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01887002 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
A Phase 2 study, sponsored by Ono Pharma USA.
- Terminated
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT01887002 is a Phase 2 study that was terminated before completion, run by Ono Pharma USA. The registered enrollment target is 39 participants.
The verdict
NCT01887002, a Phase 2 study, was terminated before completion, sponsored by Ono Pharma USA.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The objective is to evaluate whether ONO-2952 modulates visceral pain perception produced by rectal distention in female patients with IBS-D
Interventions
- DRUG Placebo comparator
- DRUG ONO-2952
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01887002
The ClinicalTrials.gov registry entry for NCT01887002 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharma USA, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo comparator is the first listed.
NCT01887002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01887002 about?
NCT01887002 is a clinical study titled "Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)". The objective is to evaluate whether ONO-2952 modulates visceral pain perception produced by rectal distention in female patients with IBS-D
What is the current status of trial NCT01887002?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2013-06.
What interventions are being tested in trial NCT01887002?
The interventions under investigation include: Placebo comparator (DRUG), ONO-2952 (DRUG).
Who is sponsoring clinical trial NCT01887002?
This trial is sponsored by Ono Pharma USA, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.